
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October, 2022

(Commission File No. 001-41157)

BIONOMICS LIMITED

(Translation of registrant's name into English)

200 Greenhill Road
Eastwood SA 5063
Tel: +618 8150 7400
(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Bionomics Limited (the "Company"), is pleased to announce that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022. The details are furnished herewith as Exhibit 99.1 to this report on Form 6-K.

EXHIBIT INDEX

Exhibit	Description
99.1	Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference



ABN 53 075 582 740

ASX ANNOUNCEMENT**4 October 2022****Bionomics to Participate in the Cantor Neurology & Psychiatry Conference**

Bionomics Limited (ASX: BNO, NASDAQ:BNOX), (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.

Errol De Souza, Bionomics' Executive Chairman, will participate in the *Emerging Broad Pipeline for Psychiatric Indications Does Not Weigh on Our Minds* panel on Friday, October 7, at 7:50am PT.

An audio webcast link for the event, when available, will be posted to Bionomics' website in the Investors-Events and Presentations section.

Released on authority of the Executive Chairman.

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr. Connor Bernstein
Vice President, Strategy and Corporate Development
cbernstein@bionomics.com.au

Kevin Gardner
LifeSci Advisors, LLC
KGardner@LifeSciAdvisors.com

About Bionomics Limited

Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au
